PTPN2 (Protein Tyrosine Phosphatase Non-Receptor Type 2, also known as TCPTP) has emerged as a premier intracellular immune checkpoint target. By negatively regulating the JAK/STAT signaling pathway, PTPN2 inhibition amplifies interferon-gamma (IFN-γ) sensing in tumor cells and enhances T-cell and NK-cell antitumor activity. Developing selective, cell-permeable inhibitors requires rigorous enzymatic profiling and robust cellular validation tools.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTPN2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTPN2 Active Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Ideal for enzymatic assays. |
View PTPN2 Products |
| Gene Delivery | PTPN2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and signaling validation. |
View PTPN2 Products |
| Benchmark Ab | Anti-PTPN2 Recombinant Antibody Recombinant positive control for western blot, IP, and intracellular flow cytometry. |
View PTPN2 Products |
| Validator | PTPN2 siRNA Set Target-specific knockdown verification to confirm target engagement phenotypes. |
View PTPN2 Products |
| Related Target A | PTPN1 (PTP1B) High-homology family member. Essential for selectivity counter-screening. |
View PTPN1 Products |
| Related Target B | JAK1 Direct downstream substrate of PTPN2. Crucial for functional readout assays. |
View JAK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PTPN1 (PTP1B) Selectivity Screening | High-purity active PTPN1 and PTPN2 proteins available for side-by-side enzymatic profiling. |
| Cellular Target Engagement | Lentivirus-driven PTPN2 overexpression and siRNA knockdown systems for in vitro validation. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and reference controls included. |
| False Positives | Validated siRNA sets included for target-specificity and phenotype rescue checks. |
Live PTPN2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTPN2 therapeutics is intensifying, with major players shifting focus from traditional systemic immunotherapies to targeted intracellular checkpoint inhibitors. As first-generation small molecule inhibitors enter early-phase clinical trials, the next wave of R&D is targeting synergistic combinations with PD-(L)1 blockades and developing highly selective degraders (PROTACs) to overcome the highly charged active-site challenge of classical phosphatases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | AbbVie, Calico Life Sciences | Advanced Solid Tumors | Enzymatic Selectivity Assay (Need PTPN2 vs PTPN1 active proteins) |
| PROTAC (Degrader) | Academic / Biotech Partnerships | Hematological & Solid Malignancies | Degradation Kinetics Validation (Need Lentivirus for stable reporter lines) |
| Gene Therapy / siRNA | Preclinical Startups | Oncology Immunotherapy | Knockdown Efficacy Validation (Need high-specificity siRNA / qPCR controls) |